Head-to-head · free

Accenture plc vs Exascale Labs

ACN vs XLAB — return on capital, cash generation, margins and balance sheet side by side.

ACN

5 / 5

measures where ACN leads

XLAB

0 / 5

measures where XLAB leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureACN · FY2026XLAB · FY2026
Revenue$18.0B$14.8M
Net income$1.8B(12.2M)
Revenue growth (yearly, multi-year)4.6%—
Free cash flow$11.6B—
Free cash flow margin64.4%—
Net cash / (debt)——
ROIC20.8%—
Return on equity25.8%—
Gross margin31.9%15.8%
Operating margin14.7%-43.4%
Net debt / EBITDA-0.55x1.39x

Figures are as reported by each company; latest fiscal year shown.

Where Accenture plc's cash went (FY2026)

Capital spending
$742.7M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ACN profile →

Where Exascale Labs's cash went (FY2026)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full XLAB profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons